AdultPediatricDosage Forms & Strengths intravenous solution: Schedule IV 5mg/mL (100mg/20mL single-dose vial) Postpartum Depression Indicated for treatment of postpartum depression (PPD) Administer as a continuous IV infusion over a total of 60 hr (2.5 days) in a monitored health setting that is able to intervene as necessary with continuous pulse oximetry Dosing 0-4 hours: Initiate at 30 mcg/kg/hr 4-24 hours: Increase to 60 mcg/kg/hr 24-52 hours: Increase to 90 mcg/kg/hr (if not tolerated, consider reducing to 60 mcg/kg/hr) 52-56 hours: Decrease to 60 mcg/kg/hr 56-60 hours: Decrease to 30 mcg/kg/hr Dosage Modifications Excessive sedation If excessive sedation occurs at any time, stop infusion until symptoms resolve May resume infusion at the same or lower dose as clinically appropriate Hypoxia Immediately stop the infusion if pulse oximetry reveals hypoxia After hypoxia, do not resume the infusion Renal impairment Mild-to-severe (eGFR ≥15 mL/min/1.73m2): No dose adjustment necessary End-stage renal disease (eGFR <15 mL/min/1.73m2): Avoid use; potential accumulation of the solubilizing agent used for brexanolone (ie, betadex sulfobutyl ether sodium) Hepatic impairment No dose adjustment necessary Dosing Considerations Healthcare provider must be available on site to continuously monitor the patient, and intervene as necessary, for the duration of the infusion Monitor for hypoxia using continuous pulse oximetry equipped with an alarm Assess for excessive sedation q2hr during planned, nonsleep periods Initiate treatment early enough during the day to allow for recognition of excessive sedationDosage Forms & Strengths intravenous solution: Schedule IV 5mg/mL (100mg/20mL single-dose vial) Postpartum Depression Indicated for treatment of postpartum depression (PPD) in adults and pediatric patients aged ≥15 years Administer as a continuous IV infusion over a total of 60 hr (2.5 days) in a monitored health setting that can intervene as necessary with continuous pulse oximetry Dosing 0-4 hours: Initiate at 30 mcg/kg/hr 4-24 hours: Increase to 60 mcg/kg/hr 24-52 hours: Increase to 90 mcg/kg/hr (if not tolerated, consider reducing to 60 mcg/kg/hr) 52-56 hours: Decrease to 60 mcg/kg/hr 56-60 hours: Decrease to 30 mcg/kg/hr Dosage Modifications Excessive sedation If excessive sedation occurs at any time, stop infusion until symptoms resolve May resume infusion at the same or lower dose as clinically appropriate Hypoxia Immediately stop the infusion if pulse oximetry reveals hypoxia After hypoxia, do not resume the infusion Renal impairment Mild-to-severe (eGFR ≥15 mL/min/1.73m2): No dose adjustment necessary End-stage renal disease (eGFR <15 mL/min/1.73m2): Avoid use; potential accumulation of the solubilizing agent used for brexanolone (ie, betadex sulfobutyl ether sodium) Hepatic impairment No dose adjustment necessary Dosing Considerations Healthcare provider must be available on site to continuously monitor the patient, and intervene as necessary, for the duration of the infusion Monitor for hypoxia using continuous pulse oximetry equipped with an alarm Assess for excessive sedation q2hr during planned, nonsleep periods Initiate treatment early enough during the day to allow for recognition of excessive sedationInteraction CheckerEnter a drug name and brexanoloneNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (0)Serious - Use Alternative (3)metoclopramide intranasalbrexanolone, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.olopatadine intranasalbrexanolone and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. selinexorselinexor, brexanolone. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.Monitor Closely (176)acetaminophen/phenyltoloxaminebrexanolone, acetaminophen/phenyltoloxamine. Either increases toxicity of the other by sedation. Use Caution/Monitor.acrivastinebrexanolone, acrivastine. Either increases toxicity of the other by sedation. Use Caution/Monitor.acrivastine and brexanolone both increase sedation. Use Caution/Monitor.alfentanilbrexanolone, alfentanil. Either increases toxicity of the other by sedation. Use Caution/Monitor.alprazolambrexanolone, alprazolam. Either increases toxicity of the other by sedation. Use Caution/Monitor.amisulprideamisulpride and brexanolone both increase sedation. Use Caution/Monitor.amobarbitalbrexanolone, amobarbital. Either increases toxicity of the other by sedation. Use Caution/Monitor.arbaclofenbrexanolone, arbaclofen. Either increases toxicity of the other by sedation. Use Caution/Monitor.aripiprazolebrexanolone, aripiprazole. Either increases toxicity of the other by sedation. Use Caution/Monitor.asenapinebrexanolone, asenapine. Either increases toxicity of the other by sedation. Use Caution/Monitor.asenapine transdermalasenapine transdermal and brexanolone both increase sedation. Use Caution/Monitor.avapritinibavapritinib and brexanolone both increase sedation. Use Caution/Monitor.baclofenbrexanolone, baclofen. Either increases toxicity of the other by sedation. Use Caution/Monitor.benperidolbrexanolone, benperidol. Either increases toxicity of the other by sedation. Use Caution/Monitor.benzhydrocodone/acetaminophenbrexanolone, benzhydrocodone/acetaminophen. Either increases toxicity of the other by sedation. Use Caution/Monitor.brexpiprazolebrexanolone, brexpiprazole. Either increases toxicity of the other by sedation. Use Caution/Monitor.brimonidinebrimonidine and brexanolone both increase sedation. Use Caution/Monitor.brivaracetambrexanolone, brivaracetam. Either increases toxicity of the other by sedation. Use Caution/Monitor.brompheniraminebrexanolone, brompheniramine. Either increases toxicity of the other by sedation. Use Caution/Monitor.buprenorphinebrexanolone, buprenorphine. Either increases toxicity of the other by sedation. Use Caution/Monitor.buprenorphine buccalbrexanolone, buprenorphine buccal. Either increases toxicity of the other by sedation. Use Caution/Monitor.buprenorphine subdermal implantbrexanolone, buprenorphine subdermal implant. Either increases toxicity of the other by sedation. Use Caution/Monitor.buprenorphine transdermalbrexanolone, buprenorphine transdermal. Either increases toxicity of the other by sedation. Use Caution/Monitor.buprenorphine, long-acting injectionbrexanolone, buprenorphine, long-acting injection. Either increases toxicity of the other by sedation. Use Caution/Monitor.buspironebrexanolone, buspirone. Either increases toxicity of the other by sedation. Use Caution/Monitor.butabarbitalbrexanolone, butabarbital. Either increases toxicity of the other by sedation. Use Caution/Monitor.butalbitalbrexanolone, butalbital. Either increases toxicity of the other by sedation. Use Caution/Monitor.butorphanolbrexanolone, butorphanol. Either increases toxicity of the other by sedation. Use Caution/Monitor.calcium/magnesium/potassium/sodium oxybatesbrexanolone, calcium/magnesium/potassium/sodium oxybates. Either increases toxicity of the other by sedation. Use Caution/Monitor.carbamazepinebrexanolone, carbamazepine. Either increases toxicity of the other by sedation. Use Caution/Monitor.carbinoxaminebrexanolone, carbinoxamine. Either increases toxicity of the other by sedation. Use Caution/Monitor.cariprazinebrexanolone, cariprazine. Either increases toxicity of the other by sedation. Use Caution/Monitor.carisoprodolbrexanolone, carisoprodol. Either increases toxicity of the other by sedation. Use Caution/Monitor.cenobamatecenobamate, brexanolone. Either increases effects of the other by sedation. Use Caution/Monitor.chloral hydratebrexanolone, chloral hydrate. Either increases toxicity of the other by sedation. Use Caution/Monitor.chlordiazepoxidebrexanolone, chlordiazepoxide. Either increases toxicity of the other by sedation. Use Caution/Monitor.chlorpheniraminebrexanolone, chlorpheniramine. Either increases toxicity of the other by sedation. Use Caution/Monitor.chlorpromazinebrexanolone, chlorpromazine. Either increases toxicity of the other by sedation. Use Caution/Monitor.chlorzoxazonebrexanolone, chlorzoxazone. Either increases toxicity of the other by sedation. Use Caution/Monitor.clemastinebrexanolone, clemastine. Either increases toxicity of the other by sedation. Use Caution/Monitor.clobazambrexanolone, clobazam. Either increases toxicity of the other by sedation. Use Caution/Monitor.clonazepambrexanolone, clonazepam. Either increases toxicity of the other by sedation. Use Caution/Monitor.clonidinebrexanolone, clonidine. Either increases toxicity of the other by sedation. Use Caution/Monitor.clorazepatebrexanolone, clorazepate. Either increases toxicity of the other by sedation. Use Caution/Monitor.clozapinebrexanolone, clozapine. Either increases toxicity of the other by sedation. Use Caution/Monitor.codeinebrexanolone, codeine. Either increases toxicity of the other by sedation. Use Caution/Monitor.cyclobenzaprinebrexanolone, cyclobenzaprine. Either increases toxicity of the other by sedation. Use Caution/Monitor.cyproheptadinebrexanolone, cyproheptadine. Either increases toxicity of the other by sedation. Use Caution/Monitor.dantrolenebrexanolone, dantrolene. Either increases toxicity of the other by sedation. Use Caution/Monitor.daridorexantbrexanolone and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. desfluranebrexanolone, desflurane. Either increases toxicity of the other by sedation. Use Caution/Monitor.deutetrabenazinebrexanolone, deutetrabenazine. Either increases toxicity of the other by sedation. Use Caution/Monitor.dexbrompheniraminebrexanolone, dexbrompheniramine. Either increases toxicity of the other by sedation. Use Caution/Monitor.dexchlorpheniraminebrexanolone, dexchlorpheniramine. Either increases toxicity of the other by sedation. Use Caution/Monitor.diazepambrexanolone, diazepam. Either increases toxicity of the other by sedation. Use Caution/Monitor.diazepam intranasaldiazepam intranasal, brexanolone. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.difelikefalindifelikefalin and brexanolone both increase sedation. Use Caution/Monitor.dimenhydrinatebrexanolone, dimenhydrinate. Either increases toxicity of the other by sedation. Use Caution/Monitor.diphenhydraminebrexanolone, diphenhydramine. Either increases toxicity of the other by sedation. Use Caution/Monitor.diphenoxylate hclbrexanolone, diphenoxylate hcl. Either increases toxicity of the other by sedation. Use Caution/Monitor.dosulepinbrexanolone, dosulepin. Either increases toxicity of the other by sedation. Use Caution/Monitor.doxylaminebrexanolone, doxylamine. Either increases toxicity of the other by sedation. Use Caution/Monitor.droperidolbrexanolone, droperidol. Either increases toxicity of the other by sedation. Use Caution/Monitor.efavirenzbrexanolone, efavirenz. Either increases toxicity of the other by sedation. Use Caution/Monitor.emedastinebrexanolone, emedastine. Either increases toxicity of the other by sedation. Use Caution/Monitor.esketamine intranasalbrexanolone, esketamine intranasal. Either increases toxicity of the other by sedation. Use Caution/Monitor.estazolambrexanolone, estazolam. Either increases toxicity of the other by sedation. Use Caution/Monitor.eszopiclonebrexanolone, eszopiclone. Either increases toxicity of the other by sedation. Use Caution/Monitor.ethanolbrexanolone, ethanol. Either increases toxicity of the other by sedation. Use Caution/Monitor.ethosuximidebrexanolone, ethosuximide. Either increases toxicity of the other by sedation. Use Caution/Monitor.ethotoinbrexanolone, ethotoin. Either increases toxicity of the other by sedation. Use Caution/Monitor.ezogabinebrexanolone, ezogabine. Either increases toxicity of the other by sedation. Use Caution/Monitor.felbamatebrexanolone, felbamate. Either increases toxicity of the other by sedation. Use Caution/Monitor.fenfluraminefenfluramine, brexanolone. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration with drugs that increase serotoninergic effects may increase the risk of serotonin syndrome.fentanylbrexanolone, fentanyl. Either increases toxicity of the other by sedation. Use Caution/Monitor.fentanyl intranasalbrexanolone, fentanyl intranasal. Either increases toxicity of the other by sedation. Use Caution/Monitor.fentanyl transdermalbrexanolone, fentanyl transdermal. Either increases toxicity of the other by sedation. Use Caution/Monitor.fentanyl transmucosalbrexanolone, fentanyl transmucosal. Either increases toxicity of the other by sedation. Use Caution/Monitor.flibanserinbrexanolone, flibanserin. Either increases toxicity of the other by sedation. Use Caution/Monitor.fluphenazinebrexanolone, fluphenazine. Either increases toxicity of the other by sedation. Use Caution/Monitor.flurazepambrexanolone, flurazepam. Either increases toxicity of the other by sedation. Use Caution/Monitor.fosphenytoinbrexanolone, fosphenytoin. Either increases toxicity of the other by sedation. Use Caution/Monitor.gabapentinbrexanolone, gabapentin. Either increases toxicity of the other by sedation. Use Caution/Monitor.gabapentin, brexanolone. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.gabapentin enacarbilbrexanolone, gabapentin enacarbil. Either increases toxicity of the other by sedation. Use Caution/Monitor.gabapentin enacarbil, brexanolone. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.ganaxolonebrexanolone and ganaxolone both increase sedation. Use Caution/Monitor.guanfacinebrexanolone, guanfacine. Either increases toxicity of the other by sedation. Use Caution/Monitor.haloperidolbrexanolone, haloperidol. Either increases toxicity of the other by sedation. Use Caution/Monitor.hydrocodonebrexanolone, hydrocodone. Either increases toxicity of the other by sedation. Use Caution/Monitor.hydromorphonebrexanolone, hydromorphone. Either increases toxicity of the other by sedation. Use Caution/Monitor.hydroxyzinebrexanolone, hydroxyzine. Either increases toxicity of the other by sedation. Use Caution/Monitor.iloperidonebrexanolone, iloperidone. Either increases toxicity of the other by sedation. Use Caution/Monitor.isofluranebrexanolone, isoflurane. Either increases toxicity of the other by sedation. Use Caution/Monitor.ketaminebrexanolone, ketamine. Either increases toxicity of the other by sedation. Use Caution/Monitor.lamotriginebrexanolone, lamotrigine. Either increases toxicity of the other by sedation. Use Caution/Monitor.lasmiditanlasmiditan, brexanolone. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.lemborexantlemborexant, brexanolone. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects. .levetiracetambrexanolone, levetiracetam. Either increases toxicity of the other by sedation. Use Caution/Monitor.levorphanolbrexanolone, levorphanol. Either increases toxicity of the other by sedation. Use Caution/Monitor.lorazepambrexanolone, lorazepam. Either increases toxicity of the other by sedation. Use Caution/Monitor.loxapinebrexanolone, loxapine. Either increases toxicity of the other by sedation. Use Caution/Monitor.loxapine inhaledbrexanolone, loxapine inhaled. Either increases toxicity of the other by sedation. Use Caution/Monitor.loxicodegolbrexanolone, loxicodegol. Either increases toxicity of the other by sedation. Use Caution/Monitor.lurasidonebrexanolone, lurasidone. Either increases toxicity of the other by sedation. Use Caution/Monitor.maprotilinebrexanolone, maprotiline. Either increases toxicity of the other by sedation. Use Caution/Monitor.meclizinebrexanolone, meclizine. Either increases toxicity of the other by sedation. Use Caution/Monitor.meperidinebrexanolone, meperidine. Either increases toxicity of the other by sedation. Use Caution/Monitor.meprobamatebrexanolone, meprobamate. Either increases toxicity of the other by sedation. Use Caution/Monitor.metaxalonebrexanolone, metaxalone. Either increases toxicity of the other by sedation. Use Caution/Monitor.methadonebrexanolone, methadone. Either increases toxicity of the other by sedation. Use Caution/Monitor.methocarbamolbrexanolone, methocarbamol. Either increases toxicity of the other by sedation. Use Caution/Monitor.methohexitalbrexanolone, methohexital. Either increases toxicity of the other by sedation. Use Caution/Monitor.methsuximidebrexanolone, methsuximide. Either increases toxicity of the other by sedation. Use Caution/Monitor.midazolambrexanolone, midazolam. Either increases toxicity of the other by sedation. Use Caution/Monitor.midazolam intranasalmidazolam intranasal, brexanolone. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound